Q2 2022
Ends Jun 29, 2022
Revenue
$0.4B
$0.4B to $0.4B
EPS
0.12
0.12 to 0.12
No analyst count
EPS: No analyst count
Apr 30, 05:56 PM UTC
stable/analyst-estimates
Healthcare
Live Price
Offline$15.30
+0.00% today
1Y Change
+0.00%
Window
Jun 20, 2025 → Jun 15, 2026
Coverage: 247 bars · Jun 20, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Rhoen-Klinikum AG (RHKJF) is a Healthcare stock with a market cap of $830.00M and listed on OTC. The stock last traded around $15.30 and up 0.0% across the available one-year price window (Jun 20, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of +21.3%, EPS growth of -23.9%, a dividend yield of 0.8%. What stands out right now is revenue +21.3%, EPS -23.9%, free cash flow -160.5% with operating margin 2.4% and ROIC 2.2%. The dividend is present but secondary, with a yield around 0.8%. Valuation is more restrained than many high-expectation growth names at P/E 24.1 and price/sales 0.5. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines RHKJF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RHKJF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RHKJF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RHKJF and SPY.
EPS Consensus
0.12
Range 0.12 → 0.12
No analyst count
vs prior: -25.1%Revenue Outlook
$0.4B
Range $0.4B → $0.4B
No analyst count
vs prior: +1.9%Consensus Spread
Lower spread suggests tighter agreement across covering analysts.
Trend
Consensus average across visible periods
Trend
Average analyst revenue estimate
Timeline
Sorted by period end date. Includes both cached rows and live fallbacks from FMP.
Next Step
Forecasts are most valuable when they sit beside comparisons, earnings setup, and the rest of the business story.